ArticleESMO gastrointestinal oncology2026

Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab.

N Martínez Lago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.